<DOC>
	<DOCNO>NCT02136030</DOCNO>
	<brief_summary>To evaluate safety efficacy liposomal amphotericin B amphotericin B deoxycholate without flucytosine follow fluconazole treatment cryptococcal meningitis .</brief_summary>
	<brief_title>Liposomal Amphotericin B Treatment Cryptococcal Meningitis</brief_title>
	<detailed_description>Subjects meet eligible requirement randomize study group （Lipo-AB）or control group（Amphotericin B deoxycholate） 2:1 ratio . Subjects treated induction therapy study group control group flucytosine least 14 day , follow consolidation therapy another 56 day CSF sterilization .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B , deoxycholate drug combination</mesh_term>
	<mesh_term>Deoxycholic Acid</mesh_term>
	<criteria>1 . Adults age least 18 year . 2 . Within 7 day prior , time screen visit , patient cryptococcus meningitis , diagnose : 1 . CSF India ink stain positive OR 2 . CSF cryptococcal antigen test positive OR 3 . CSF culture positive 3 . Patient his/her legally acceptable representative sign write informed consent form . 1 . Patients laboratory abnormality within 3 day prior screen visit : 1 . ALT &gt; 5x UNL , 2 . AST &gt; 5x UNL , 3 . Creatinine &gt; 2mg/dl 2 . Patient pregnant lactating . 3 . Patient participate investigational drug trial within 1 month enter study . 4 . Patient indication another systemic antifungal drug would need addition assign drug study . 5 . Patient contraindication amphotericin B azole . 6 . Patient available lumbar puncture . 7 . Patient life expectancy le 5 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Cryptococcal meningitis</keyword>
</DOC>